Revolution Medicines (RVMD) insider sells 3,120 shares after exercising options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Revolution Medicines, Inc. (RVMD) insider Anthony Mancini reported a pre-planned exercise-and-sell transaction in company stock. On April 27, 2026, he exercised stock options for 3,120 shares of common stock at an exercise price of $33.62 per share.
The same day, he executed three open-market sales totaling 3,120 shares of common stock at weighted average prices around $131–$134 per share, under a Rule 10b5-1 trading plan adopted on December 24, 2025. Following these transactions, he held 54,400 shares or restricted stock units directly, according to the filing.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 3,120 shares ($413,129)
Net Sell
5 txns
Insider
Mancini Anthony
Role
See Remarks
Sold
3,120 shs ($413K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 3,120 | $0.00 | -- |
| Exercise | Common Stock | 3,120 | $33.62 | $105K |
| Sale | Common Stock | 1,671 | $131.6619 | $220K |
| Sale | Common Stock | 1,049 | $132.8768 | $139K |
| Sale | Common Stock | 400 | $134.335 | $54K |
Holdings After Transaction:
Stock Option (Right to Buy) — 109,230 shares (Direct, null);
Common Stock — 57,520 shares (Direct, null)
Footnotes (1)
- Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. Includes 54,400 Restricted Stock Units. This transaction was executed in multiple trades at prices ranging from $131.08 to $132.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $132.37 to $133.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $134.04 to $134.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Key Figures
Shares sold: 3,120 shares
Exercise price: $33.62 per share
Sale price range (low set): $131.08–$132.06
+4 more
7 metrics
Shares sold
3,120 shares
Open-market sales of common stock on April 27, 2026
Exercise price
$33.62 per share
Stock option exercise for 3,120 shares
Sale price range (low set)
$131.08–$132.06
First group of trades, weighted-average price reported
Sale price range (mid set)
$132.37–$133.35
Second group of trades, weighted-average price reported
Sale price range (high set)
$134.04–$134.60
Third group of trades, weighted-average price reported
Post-transaction equity units
54,400 units
Restricted Stock Units held after transactions
Option expiration
March 31, 2035
Expiration date of stock option covering 3,120 shares
Key Terms
Rule 10b5-1 trading plan, Restricted Stock Units, Stock Option (Right to Buy), weighted average price, +1 more
5 terms
Rule 10b5-1 trading plan financial
"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Restricted Stock Units financial
"Includes 54,400 Restricted Stock Units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
vesting financial
"shares subject to the option will vest on the first year anniversary measured from April 1, 2025"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transactions did Anthony Mancini report in RVMD stock?
Anthony Mancini exercised options for 3,120 shares of Revolution Medicines common stock and sold 3,120 shares in open-market transactions on April 27, 2026. The exercise price was $33.62 per share, while sale prices ranged around $131–$134 per share.
Were Anthony Mancini’s RVMD stock sales pre-planned under a Rule 10b5-1 plan?
Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. Such plans schedule trades in advance, making the timing more routine and less indicative of short-term views.
What stock option terms were disclosed for Anthony Mancini in RVMD?
The filing shows a stock option for 3,120 shares of Revolution Medicines common stock with an exercise price of $33.62 per share and an expiration date of March 31, 2035. Vesting began April 1, 2025, with full vesting expected over four years, subject to continued service.
At what prices were Anthony Mancini’s RVMD trades executed?
The sales were executed in multiple trades within price ranges of $131.08–$132.06, $132.37–$133.35, and $134.04–$134.60 per share. The Form 4 reports weighted average sale prices for each transaction and notes that full trade details are available upon request.